SSMC passes 1,260 robotic surgeries as Abu Dhabi expands complex care

Sheikh Shakhbout Medical City (SSMC) in Abu Dhabi has performed more than 1,260 robotic-assisted surgeries since launching its programme in 2020, according to Abu Dhabi Media Office.

The highest-stakes readers are COOs, CFOs and medical directors. For Dubai clinics regulated by the Dubai Health Authority (DHA), the immediate issue is referral competition in complex surgery. For Abu Dhabi providers licensed by the Department of Health - Abu Dhabi (DOH Abu Dhabi), the issue is whether robotic capability becomes a marker of tertiary-care readiness. For Northern Emirates operators under the Ministry of Health and Prevention (MOHAP), the question is when to refer rather than invest.

What SSMC added

SSMC, a subsidiary of PureHealth, said the programme now performs more than 500 robotic-assisted procedures a year. It started with one robotic platform and four procedures. It now covers thoracic surgery, urology, oncology, orthopaedics, neurosurgery and general surgery.

The hospital said robotic volumes rose 42% in the first half of 2026 compared with the same period in 2025. First-quarter procedures increased from 87 to 131. Second-quarter procedures increased from 119 to 161.

“Over the past few years, robotic-assisted surgery has become an integral part of how we approach some of the most complex procedures, enabling greater precision while supporting minimally invasive treatment pathways for our patients.” Dr Marwan Al Kaabi, Chief Executive Officer, Sheikh Shakhbout Medical City

Recent procedures cited by SSMC include single-port robotic thoracic sympathectomy for hyperhidrosis and emergency robotic urology surgery. The programme has four robotic systems for general surgery, including two orthopaedic platforms and one neurosurgical platform acquired in 2026.

Why clinics and insurers should care

For clinics, the expansion changes the referral map. A Dubai outpatient clinic seeing a surgical candidate now has to compare DHA-licensed hospital pathways with Abu Dhabi tertiary options. That matters in urology, orthopaedics and bariatric surgery, where patients often compare recovery time, surgeon volume and insurance approval before selecting a hospital.

For insurers, robotic surgery raises a narrower question: when does the robot change the payable episode of care? Daman, Thiqa and Sukoon coverage terms depend on network status, medical necessity, prior authorisation and the patient’s benefit schedule. Operators should avoid quoting a single robotic-surgery price unless they can tie it to a CPT or local billing code, surgeon fee, implant use, length of stay and insurer approval.

Patients in the UAE commonly face different out-of-pocket exposure for the same operation depending on plan design, co-insurance, network tier and consumables. A practical quote should separate four items:

• Surgeon, anaesthesia and theatre fees for the specific procedure.
• Robot-related consumables, implants and disposable instruments.
• Expected inpatient stay, day-case status or ICU requirement.
• Insurer approval status, co-pay, deductible and exclusions.

Where a provider does not publish an AED package, the actionable number is the insurer’s written pre-authorisation amount. Clinics should ask the receiving hospital for a written estimate before referral. Finance teams should compare that estimate with the approved benefit and the patient’s expected co-payment.

Operational implications

Medical directors should treat SSMC’s numbers as a credentialing signal, rather than a blanket quality claim. The checkable facts are volume, trained surgeons, supported specialties and platform availability. SSMC said 100% of its bariatric and thoracic surgeons and 80% of its general surgeons are trained in advanced robotic-assisted procedures.

COOs considering their own robotic programme need a harder internal test. The capital case depends on annual eligible volume, theatre utilisation, surgeon adoption, maintenance cost, disposable cost and the payer mix. A clinic with low surgical volume may get more value from a formal referral pathway than from buying a platform.

For Abu Dhabi, DOH Abu Dhabi remains the relevant regulator for facility licensing, clinician licensing and health-system policy. DHA governs Dubai facilities and professionals. MOHAP governs federal licensing in the Northern Emirates. Any cross-emirate referral workflow should check the patient’s plan network, the surgeon’s licence, and whether the receiving facility is authorised for the planned procedure.

The next marker is payer behaviour. If insurers approve robotic procedures more consistently for selected indications, UAE hospitals will have a clearer business case. If approvals stay case-by-case, robotic surgery will remain concentrated in high-volume tertiary centres. For licensed clinics and providers, readers can cross-check providers through the UAE Open Healthcare Directory before making referral or partnership decisions.